Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is metabolised inside cells to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I complex, stabilising the transient single‑strand breaks that occur during DNA replication. By preventing relegation of these breaks, the drug induces irreversible DNA damage, leading to apoptosis of rapidly dividing cancer cells.

The dosing regimen for Irinotecan Kabi is determined by the prescribing oncologist based on factors such as the patient’s body surface area, disease stage, and concurrent therapies. The prescriber calculates the appropriate milligram per square meter dose and schedules the intravenous infusion according to the selected treatment protocol.

The safety of Irinotecan Kabi in pregnancy and lactation has not been established. Animal studies have shown embryotoxic effects, and the drug is classified as contraindicated for use in pregnant or nursing women unless the potential benefit outweighs the potential risk. Consultation with a specialist is essential before exposure.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details—including cold‑chain logistics if needed—and the necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, whereas its primary alternative in colorectal cancer regimens is oxaliplatin, a platinum‑based DNA cross‑linker. Irinotecan primarily induces single‑strand DNA breaks, while oxaliplatin forms DNA adducts. Clinical choice depends on prior therapy, toxicity profile, and patient tolerance, as each agent has distinct efficacy and side‑effect considerations.

Irinotecan Kabi must be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use, and any prepared infusion should be administered promptly according to aseptic technique to maintain stability and potency.

Irinotecan Kabi is supplied as an injectable solution for intravenous infusion. The medication is diluted in an appropriate carrier fluid and administered over a specified period, usually 30 to 90 minutes, under the supervision of qualified healthcare professionals. Infusion parameters are set according to the prescribing protocol and patient tolerance.

The most critical adverse events include severe neutropenia with fever, life‑threatening colitis or diarrhea, and hypersensitivity reactions that can progress to anaphylaxis. Prompt recognition of these signs, regular laboratory monitoring, and immediate medical intervention are essential to mitigate morbidity and mortality associated with the drug.

Irinotecan Kabi is contraindicated in patients with known hypersensitivity to irinotecan or any of its excipients, those with active severe infections, or individuals with recent bowel obstruction. Caution is also advised for patients with significant hepatic impairment, as drug clearance may be reduced, increasing the risk of toxicity.